Emerging Company and Innovator's Showcase

Sponsored By:
&

Click here for presentation schedule

Acceleron Pharma, Inc.- Developing therapies that regulate the TGFb superfamily of proteins, which play fundamental roles in the growth and repair of tissues such as blood, bone, muscle and blood vessels.

Adhaere Pharmaceuticals, Inc. - Developing novel small molecule therapeutics for the treatment of inflammatory and autoimmune diseases, focusing on lupus and lupus nephritis.

ADS Biotechnology – Developing a novel blood volume expander for use in the treatment of conditions result in Capillary Leak Syndrome (CLS).

Andarix Pharmaceuticals – Developing a novel, best-in-class therapy for lung and other cancers based on the radio-labeled somatostatin peptide P2045.

Aposcience AG – Developing a therapy for tissue regeneration in acute and chronic myocardial ischemia as well as cutaneous wound healing and skin regeneration.

Biomedica Management Corporation - Developing novel treatments in coagulopathy-related conditions with civilian and military applications (wound healing, fluid resuscitation, and sepsis).

Blue Highway, Inc. – Developing frequency doubling technology (FDT), an automated tool that can detect sensitivity and VF defects for glaucoma testing

BREONICS, Inc. - Commercializing an innovative organ regeneration technology called EMS to address the shortage of transplantable kidneys

Brookhaven National Laboratory - Dr. Walter F. Mangel: development of new antiviral agents using adenovirus as the model system. A novel aspect of the current research is the identification of non-active site targets for antiviral agents in the adenovirus proteinase.

Certerra, Inc. – Developing an automated microscopy, called serial two-photon (STP) tomography, for imaging whole mouse brains and a pipeline of image processing and computational methods for analysis of the acquired mouse brain datasets.

Citta Pharmaceuticals – Developing a novel HAT activator, YF2, to improve neuronal communication for the treatment of Alzheimer's disease

Columbia University - Dr. Andreas Hielscher

Curemark, LLC – Developing innovative therapeutic treatments for neurological disorders including Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD) and Parkinson’s disease.

Endacea, Inc. - Developing a series of A1 adenosine receptor antagonists as disease modifying drug candidates for sepsis and renal impairment.

Ezose Sciences, Inc. – Developing a high-throughput solution that can deliver both qualitative and quantitative data on glycans of biological and clinical interest across a range of biological sample types, using a fully automated robotic platform

Genomic Expression - Commercializing first generation digital array leading to an abbreviated process of developing diagnostics for personalized medicine.

ImmunoGenes AG – Developing transgenic mice with an improved immune response for the development of antibodies against weakly immunogenic targets. .

Immunome, Inc.  – Developing a monoclonal therapy for use with infectious diseases, neurological illnesses, oncology and biodefense.

Inhibikase Therapeutics, Inc. – Developing small molecule to prevent drug-induced progressive multifocal leukoencephalopath, a fatal brain disorder that is induced by monoclonal antibody therapies for arthritis, lupus and MS.

Integrated Tissue Dynamics, LLC – Developing a unique technique for understanding signaling and basic biology in the context of complex systems applicable to any step in any type of drug development including discovery, validation and preclinical to Phase IV post-marketing studies.

Kalos Therapeutics, Inc. - Developing a therapeutic peptide based on the atrial natriuretic peptide family of peptides that have antiproliferative activity against a number of different cancer cell types, including pancreatic cancer.

Lypro Biosciences – Developing the NanoDisk (ND) platform for marrying antibody-like targeting with chemotherapeutics.

MarrowSource Therapeutics International - Commercializing a technology to enable the expansion of hematopoetic stem cells and progenitor cells that are used to accelerate bone marrow recovery following chemotherapy, or radiation exposure.

Mico Biopharm - Developing of a vaccine against TB,  localized to the pulmonary system.

Mirimus, Inc. - Producing custom genetically engineered mouse models with reverse gene silencing capabilities by harnessing the power of RNA interference.

MSDx, Inc.  – Developing a novel source of biomarkers that relates to the disease activity of a Multiple Sclerosis patient.

PRISM BioLab Corporation – Developing the compound PRI-724, expected to provide a new therapeutic course of treatment for "resistant" strains of cancer cells in a broad array of organ settings.

Provia Biologics – Developing a method to measure small molecules and perform histology on exactly the same portion of tissue.

Stony Brook University - Soluble E-cadherin: A novel therapeutic cancer target in the tumor microenvironment and An Attenuated Live Vaccine

SUNY Downstate Medical Center – Developing methods for detecting folate receptor autoantibodies in mothers and infants to provide reliable and least invasive procedure for identifying this autoimmune disorder for prompt therapeutic intervention.

TechnoVax – Developing a new way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle vaccines for infectious diseases including influenza, HIV and cancer.

Vapogenix, Inc – Developing a fast-acting, low-cost topical that can treat pain without the systemic side effects of existing analgesics.

Vybion, Inc. - Developing a therapeutic for the treatment of Huntington’s disease that restores the proteolytic degradation of the HDpolyQ mutant, thereby preventing accumulation, aggregation and neuron cell death.